CMS Issues Coverage Guidance on GLP-1 Anti-Obesity Drugs: Implications for Health Plans Posted on April 5, 2024 CMS Issued Coverage Guidance on GLP-1 Anti-Obesity Drugs Requiring Considerations for Health Plans GLP-1s (glucagon-like peptide 1 agonist) came up in the news again after the Centers for Medicare and Medicaid Services (CMS) issued coverage guidance on GLP-1 anti-obesity drugs with expanded indications on March 20, 2024.* Since the inception of Medicare Part D, drugs used for weight loss have been excluded from basic coverage
So when one of our physicians or nurse practitioners sees a patient with obesity and we are prescribing, deprescribing, managing side effects or addressing abnormal laboratory values, we work with the PCP, we communicate with the PCP to try to create a coordinated approach so that the patient is getting excellent primary care to address the multitude of clinical conditions that they may have, while also receiving excellent specialty care to manage this underlying complicated disease state
Its main effect is preventing the hormonal redistribution of fat to the abdomen
Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)-cystine transporter: a new action for an old drug
Used in laboratory research involving metabolic signaling pathways This compound is commonly evaluated in preclinical and laboratory settings investigating metabolic disorders, energy balance, and combination peptide protocols
Barrier-Supporting & Gentle on Skin: Designed to support the skins moisture barrier, this soothing PDRN ampoule helps calm dryness and discomfort while maintaining healthy-looking skinsuitable for sensitive, dry, and all skin types
